Beta Bionics (NASDAQ:BBNX) Price Target Raised to $20.00 at Bank of America

Beta Bionics (NASDAQ:BBNX) had its target price raised by equities researchers at Bank of America from $18.00 to $20.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. Bank of America‘s price objective would suggest a potential upside of 4.28% from the stock’s previous close.

Other research analysts have also issued research reports about the company. William Blair initiated coverage on Beta Bionics in a research report on Friday, August 21st. They set a “market perform” rating on the stock. Truist Financial reiterated a “buy” rating and issued a $23.00 price target (up from $22.00) on shares of Beta Bionics in a research report on Tuesday. The Goldman Sachs Group raised their price objective on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings raised shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Finally, Leerink Partners boosted their price target on Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Beta Bionics presently has an average rating of “Moderate Buy” and an average price target of $21.90.

Beta Bionics Trading Up 14.6%

NASDAQ:BBNX traded up $2.45 during midday trading on Tuesday, hitting $19.18. 886,469 shares of the company were exchanged, compared to its average volume of 1,143,133. Beta Bionics has a fifty-two week low of $8.80 and a fifty-two week high of $32.71. The company has a market capitalization of $862.91 million, a PE ratio of -11.53 and a beta of 3.37. The company has a fifty day simple moving average of $17.30 and a 200 day simple moving average of $13.82.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The company had revenue of $32.01 million for the quarter. As a group, equities research analysts expect that Beta Bionics will post -2.1 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Stephen Feider sold 6,675 shares of Beta Bionics stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $127,559.25. Following the completion of the transaction, the chief financial officer directly owned 159,378 shares in the company, valued at approximately $3,045,713.58. This trade represents a 4.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark Hopman sold 36,870 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $18.46, for a total value of $680,620.20. Following the completion of the sale, the insider owned 87,157 shares in the company, valued at approximately $1,608,918.22. This represents a 29.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 70,132 shares of company stock valued at $1,284,623 over the last 90 days. 5.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BBNX. BlackRock Inc. bought a new position in shares of Beta Bionics in the second quarter valued at approximately $52,340,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Beta Bionics during the fourth quarter worth approximately $40,437,000. Eversept Partners LP lifted its holdings in Beta Bionics by 108.6% in the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after buying an additional 736,576 shares during the period. 12 West Capital Management LP acquired a new stake in Beta Bionics during the 4th quarter worth $17,520,000. Finally, Bruce & Co. Inc. bought a new stake in shares of Beta Bionics during the 1st quarter valued at $5,518,000.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The FDA cleared Beta Bionics’ Mint insulin patch pump, which uses a reusable and disposable design, does not require recharging, supports leading continuous glucose monitors, and can be controlled by smartphone. The product is expected to expand the company’s addressable market, with a potential launch in 2027. Beta Bionics Announces FDA Clearance of Mint
• Positive Sentiment: Beta Bionics and Senseonics announced plans to integrate Senseonics’ year-long Eversense 365 continuous glucose monitor with the iLet Bionic Pancreas, targeting a commercial launch in the fourth quarter of 2026. The partnership could improve product functionality and adoption. Senseonics Announces Partnership with Beta Bionics
• Neutral Sentiment: Robert W. Baird raised its price target from $14 to $16 but maintained a neutral rating. The new target remains below the stock’s referenced price, suggesting the analyst sees limited near-term upside despite the recent recovery.
• Negative Sentiment: Beta Bionics lowered its 2026 revenue guidance, raising concerns about near-term demand, execution, and the pace of commercial growth even as it advances new products. Beta Bionics Lowers 2026 Revenue Guidance
• Negative Sentiment: Several law firms publicized a securities class-action lawsuit covering investors who purchased BBNX shares from July 30, 2025, through February 24, 2026. The allegations include overstated iLet safety, efficacy, and clinical outcomes, as well as claims that more than 18,000 customer complaints were not properly reported or investigated. The lead-plaintiff deadline is November 3, 2026. The allegations have not been proven, but the litigation creates legal, financial, and reputational risk. BBNX Shareholder Alert

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.